SINTROM 4 MG
ACENOCOUMAROL : 4 MG · DIN 00010391 · PALADIN PHARMA INC.
Health Canada status: CANCELLED POST MARKET
What is SINTROM?
SINTROM 4 MG contains ACENOCOUMAROL : 4 MG. It is listed in the Health Canada Drug Product Database under DIN 00010391, held by PALADIN PHARMA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SINTROM used for?
Prophylaxis and treatment of venous thrombosis, atrial fibrillation with embolization, pulmonary embolism, and adjunct in coronary occlusion and transient cerebral ischemic attacks.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00010391 |
|---|---|
| Brand name | SINTROM |
| Generic / active ingredient | ACENOCOUMAROL : 4 MG |
| Manufacturer | PALADIN PHARMA INC. |
| Strength | 4 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AA07 ACENOCOUMAROL |
| AHFS class | 20:12.04.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Sep-2021 |
| Original market date | 1962-12-31 00:00:00 |
How is it administered?
Initial: 8-12 mg (Day 1), 4-8 mg (Day 2). Maintenance: 1-10 mg daily based on INR/prothrombin time. Take as a single daily dose at the same time.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in text.
How is it supplied?
Not specified in text.
Contraindications
States with high hemorrhage risk: blood dyscrasia, recent CNS/eye surgery, active ulcers, severe hypertension, severe liver/renal lesions, pregnancy, and hypersensitivity to coumarins.
Warnings and precautions
Potent drug with cumulative effects. Monitor via prothrombin time/INR. Avoid IM injections. Elderly require special care. Abrupt cessation not recommended; taper over 3-4 weeks.
What can be used instead?
Other Canadian products sharing ATC code B01AA07 ACENOCOUMAROL. 0 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SINTROM | 1 MG | TABLET | PALADIN PHARMA INC. | CANCELLED POST MARKET | DIN 00010383 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.